American Chemistry Council: Obstructing Formaldehyde Safeguards Then and Now – Union of Concerned Scientists (blog)

Photo: DeAntre Bryant/UCS

The chemical industry has once again staved off federal action that would protect public health, as the EPA announced last week that it would be delaying compliance dates for the long-awaited formaldehyde emission standards for composite wood productsstandards that were finalized in December 2016. This is the latest move brought to you by an industry with a long history of attacking science and an administration willing to do its bidding.

Its no surprise that industry employs tactics like manufacturing doubt, attacking scientists, and influencing policymakers in a calculated effort to delay or halt science-based safeguards. Under the Trump administration, we have already seen a host of important policies rooted in strong science rolled back or delayed, including stronger beryllium, silica, ozone, and methane standards, stream protection requirements for mining operations, vehicle fuel economy standards, coal plant wastewater standards, risk management program amendments, and mercury and air toxics standards.

Last week, The New York Times reported on the way in which Administrator Scott Pruitts EPA has loosened its regulatory grip on the business community, and especially the oil and gas industry with which Pruitt has longstanding financial ties. The President of the Western Energy Alliance, an association of oil and gas companies, told the NYT, We are so used to not being able to move an agenda forward that it has been very surprising how quickly things have changed.

But what does it mean for us when industry moves its agenda forwardespecially when that agenda involves stopping the creation of evidence-based limits for chemicals, proven unsafe, that will make their way into our homes or drinking water?

The binders used to glue together wood fibers in particleboard, plywood, and other building materials often contain formaldehyde. Photo: Rotor_DB/Creative Commons (Wikimedia).

Formaldehyde is a colorless, flammable chemical widely used in building materials, medicinal and personal care products, and furnishings. Fumes from these products can be harmful to human health, especially when they accumulate indoors at high concentrations. Acute exposure can lead to nausea, headaches, and eye, nose, throat and skin irritation, even asthma exacerbation. Chronic exposure has been linked to cancers in humans, including cancers of the nose and throat, lymphomas, and leukemia. In 2004, the International Agency for Research on Cancer concluded that formaldehyde is a human carcinogen, and the U.S. Department of Health and Human Services listed it is as a known human carcinogen in 2011.

Health impacts have been understood since the 1980s, and yet over thirty years later, there are no federal restrictions on formaldehyde emissions in the home. Without standards in place, public health is at risk. Back in 2005, the cheaply constructed emergency trailers that housed Hurricane Katrina refugees were found to have unsafe levels of formaldehyde, earning them the toxic trailers nickname, while inhabitants already dealing with displacement in the midst of an environmental disaster suffered from respiratory problems, burning eyes, and other ailments. Without controls on formaldehyde emissions, these trailers have been resold and some were even used as temporary housing for workers cleaning up the BP oil spill in the gulf in 2010. Wood products used to build and remodel homes across the country can still contain formaldehyde at potentially unsafe levels.

Then

The trade organization representing chemical companies including the makers of formaldehyde, the American Chemistry Council (ACC), worked to downplay the risks of the chemical and to delay and otherwise thwart the formaldehyde emissions rule as it was first being proposed and finalized by the EPA. The ACC created a website that touts the environmental benefits of formaldehyde, casts doubt on established health studies linking exposure to a range of ailments, and assures consumers that voluntary industry standards were strong enough to protect them. The ACC also persuaded Congress to commission the National Academies of Science to reevaluate EPA science on formaldehyde, resulting in a delay in the process lasting 3 years and reaching the same conclusion that formaldehyde should be listed as known to be a human carcinogen.

The ACC even got involved with White House-level review. In 2012, the White House Office of Management and Budget meeting record shows that it had at least five meetings with industry executives, their lobbyists, and ACC-financed lawmakers (like Senator Vitter), asking them to halt the EPA proposal, which apparently worked. After OMB-review, the EPA deleted from its cost-benefit analysis the benefits of reduced health ailments like asthma and fertility issues that a formaldehyde standard would have prevented, dropping the benefits from $278 million to $48 million annually.

Now

The formaldehyde emissions rule was issued by the EPA in December 2016, and the ACC has continued to deny the science used by the EPA and to lobby the EPA and Congress on the issue. The ACC spent nearly $1.5 million lobbying agencies and Congress on a host of issues in just the first quarter of 2017 (January to March), including on formaldehyde, hexavalent chromium, the nomination of EPA Administrator Scott Pruitt, EPAs Science Advisory Board, the HONEST Act, the Regulatory Accountability Act, Risk Management Program amendments, and even FY 2018 appropriations for the EPA.

Just this month, a study was issued that was funded by the Foundation for Chemistry Research and Initiatives (FCRI), a nonprofit organization established by the ACC. According to its financial filings the nonprofit works to address uncertainties and answer questions on health and environmental issues, taking on projects that will furnish crucial information, peer-reviewed scientific research, expert panels, and workshops to inform policy. FCRI granted a total of $425,294 of its revenue (which comes entirely from ACC)to study formaldehyde in 2012 and $425,114 to Environ International Corporation (now Ramboll Environ) and other consulting firms and research institutions to reevaluate formaldehyde data in 2014. Environ International has been called a hired gun by former OSHA administrator David Michaels, and the firm has been commissioned by several corporations to contribute to the scientific literature, including notorious tobacco company R.J. Reynolds (now Reynolds American Incorporated Services Company) and the Industrial Health Foundation (a former trade organization for industrial facilities), conducting studies with conclusions that downplayed the risks of menthol cigarettes and hexavalent chromium.

This FCRI issued grants led to several studies that helped to sow uncertainty about the potential of long-term exposure to formaldehyde to cause myeloid leukemia. A 2013 study by Environ authors funded by the FCRI and Momentive Special Chemicals Inc. (now Hexion Specialty Chemicals, Inc.), a formaldehyde-producing chemical company, used FOIA-obtained data to refute findings suggesting a link between formaldehyde exposure and leukemia. Earlier this month, the ACC touted another FCRI-funded study with the headline new study challenges formaldehyde cancer findings, after the study built upon its 2013 work and concluded that there was no causal association between formaldehyde and leukemia, of course not mentioning the very clear conflict of interest at hand. The ACC has used this study to urge the EPA not to characterize formaldehyde as linked to leukemia development.

For years now, no matter how strong the scientific consensus around an issue is, the ACC has continuously worked to obscure scientific findings and obstruct policies that are designed to protect public health and safety, all to save chemical companies time and money.

Photo: FEMA

For people like Becky Gillette, this rules enforcement cannot come soon enough. She told the New York Times, People think
that just because Congress passed the legislation five years ago, the problem has been fixed, said Becky Gillette, a Mississippi resident affected by Hurricane Katrina who was one of the first people to notice that the FEMA trailers were causing health problems. Real peoples faces and names come up in front of me when I think of the thousands of people who could get sick if this rule is not done right.

The EPAs final formaldehyde emissions rule estimates that 132 million individuals will be living in housing units where composite wood products have been installed within the past 11 years. Considering that population, the implementation of this rule will help prevent 26 to 64 nasopharyngeal cancer cases and 92,218 to 604,155 cases of eye irritation annually. These counts dont even take into consideration other health ailments and types of cancer. A delay of just three months in implementation could mean the difference between cancer diagnoses and clean bills of health for at least eight Americans with faces and names.

Theres still a chance to tell EPA to leave the compliance dates alone and move forward with the rule. The EPA is accepting comments on its decision until June 8.

For more on the American Chemistry Councils history of fighting policies that regulate chemicals produced by its member companies (think BPA, silica, and flame retardants), even when scientific evidence points to adverse health or environmental impacts, check out our 2015 report Bad Chemistry: How the Chemical Industrys Trade Association Undermines the Policies that Protect Us.

Posted in: Science and Democracy Tags: American Chemistry Council, Conflict of Interest, formaldehyde

Support from UCS members make work like this possible. Will you join us? Help UCS advance independent science for a healthy environment and a safer world.

Continued here:
American Chemistry Council: Obstructing Formaldehyde Safeguards Then and Now - Union of Concerned Scientists (blog)

Swamp Foxes working on chemistry – Journalscene.com

Swamp Fox coaches say there are some positives to take away from the 2017 Ashley Ridge Football Spring Practice.

Ashley Ridge recently wrapped up its Spring Practice with its annual Spring Game at the high school, an event that provides coaches one last chance to evaluate players going into the summer break.

We learned as a staff that we have a bunch of guys that are hardworking and play for each other, Ashley Ridge coach Kenny Walker said. Team chemistry is a goal for us and I think that we are off to a good start.

Graduation left the team with some key holes to fill. The Swamp Foxes lost their two leading rushers from last season and their leading receiver.

However, the team stands to return two quarterbacks with varsity experience, some receivers who have been in the fire and some other experienced varsity lettermen.

Rising seniors Matthew Duncan and Bryce Bryan are expected to return after seeing time behind center last season. Duncan led the team in passing, completing 87 passes for 922 yards and seven touchdowns. Bryan completed 13 of 23 pass attempts for 108 yards. Between them, they threw only two interceptions.

Bryan also has experience at other skills positions, which is something the Swamp Fox coaches like in a player.

Another goal was for us to establish some good depth and we have used the spring to work guys on both sides of the ball or at (multiple) positions on the side of the ball they are on already, Walker said. We feel that it will help us throughout the grinding season.

Rising senior JJ McAfee stands to return at the receiver position after making 23 receptions last season.

Graduation didnt hit the Swamp Fox defense as hard.

Ashley Ridge stands to return four of its top five tacklers from last season. Rising seniors J Mitchum, Owen Trephan and Nijay Hill and rising junior Ben Mitchum combined for just less than 300 tackles last season. Ben Mitchum and Trephan are linemen while J Mitchum is a linebacker and Hill a defensive back. Hombre Kennedy also stands to return to the defensive backfield after breaking up five passes and intercepting three last season.

Linebackers Darius Smith and Aveyuan Dennis and DB Rodney Oldham are among the other athletes who stand to return to the Swamp Fox defense after making considerable contributions last season.

The Ashley Ridge skills players will hone their skills this summer during passing camps and competitions. Ashley Ridge will host Fort Dorchester for a passing camp at 11:15 a.m. June 6 and host Summerville for a camp at 11 a.m. June 22.

The Swamp Foxes will send squads to the 7 on 7 competition at University of South Carolina June 9 as well as to camps at 6 p.m. June 8 at Fort Dorchester and at noon June 29 at Summerville.

Read this article:
Swamp Foxes working on chemistry - Journalscene.com

Martavis Bryant: Chemistry will ‘take time’ coming back – ESPN (blog)

Steelers receiver Martavis Bryant (10) has scored 15 touchdowns in his first 21 regular-season games.

PITTSBURGH -- Wide receiver Martavis Bryant acknowledged making a few plays in Tuesday's organized team activities, including a "quick" over-the-top play off a Ben Roethlisberger lob pass for a big gain in 11-man work.

Bryant knows he'll need many more days like this to work his way back into the Pittsburgh Steelers' offense for 2017.

"It's still going to take time," Bryant said. "With the work put in, the chemistry will come back."

Bryant, who returns to the practice field after missing all of last season for violating the league's substance-abuse policy, has attended each of the first four OTA sessions while looking to "knock the rust off," he said. Bryant is under conditional reinstatement from the NFL.

His weight is up to 225, and he believes he's maintained his elite speed on the field while creating a drug-free environment off it.

Typically, throwing to Bryant increases the chances for a big play. Bryant has scored 15 touchdowns in his first 21 regular-season games. But simply being on the field is most important to Bryant, who says he isn't worried about when or how he gets the ball.

"All I know is with trust comes consistency," Bryant said. "As long as I handle my business, the rest should come back. I'm not going to stress over that. I'm just going to continue to do what I'm doing."

See the rest here:
Martavis Bryant: Chemistry will 'take time' coming back - ESPN (blog)

Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst’s Predictions – StockNewsJournal


The Cerbat Gem
Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's Predictions
StockNewsJournal
Investors who are keeping close eye on the stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) established that the company was able to keep return on investment at -163.88 in the trailing twelve month while Reuters data showed that industry's average ...
Puma Biotechnology Inc (PBYI) Upgraded at Cowen and CompanyThe Cerbat Gem
Puma Biotechnology, Inc. (NasdaqGS:PBYI): Honing in on the TechnicalsGeneva Journal
PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Other EventsMarket Exclusive
Chaffey Breeze -BBNS -Sports Perspectives -SEC.gov
all 41 news articles »

Go here to see the original:
Earnings Clues on Puma Biotechnology, Inc. (PBYI), AGNC Investment Corp. (AGNC) Analyst's Predictions - StockNewsJournal

TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the … – PR Newswire (press release)

TAIPEI, Taiwan, May 30, 2017 /PRNewswire/ --TaiGen Biotechnology Company, Limited ("TaiGen") today announced that it has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn (Nemonoxacin) to the China Food and Drug Administration (CFDA). Taigexyn is a novel non-fluorinated quinolone antibiotic.The NDA submission is supported by a pivotal Phase 3 trial comparing intravenous formulations of Taigexyn 500 mg to levofloxacin 500 mg in 518 patients with moderate to severe community-acquired pneumonia. The clinical success rates were 91.8% for Taigexyn vs. 85.7% for levofloxacin and Taigexyn was shown to be non-inferior to levofloxacin meeting the primary endpoint of the pivotal trial.

About Taigexyn Taigexyn is a novel broad spectrum antibiotic with excellent efficacy against drug-resistant bacteria available in both oral and intravenous formulations. The oral formulation is already approved for marketing and launched in Taiwan and mainland China. In addition, Taigexyn is also partnered in Russia, Commonwealth Independent States, Turkey, Mexico, Brazil and the Latin American territory for a total 32 countries worldwide.

Read the rest here:
TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the ... - PR Newswire (press release)

Puma Biotechnology Inc (PBYI) Breaks into New 52-Week High on May 30 Session – Equities.com

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Shares of Puma Biotechnology Inc (PBYI) broke into a new 52-week high yesterday, hitting a peak of $80.20. Shares closed at $76.90 after opening at $80.15 for a move of -3.57%. The company now has a market cap of $2.84 billion.

Investors and traders can learn a lot about a stocks momentum when it sets a new 52-week high. As an example, bullish investors view a company hitting its highest price in a year as a sign of momentum and may interpret it as a signal to buy. On the other hand, bearish investors could view a new 52-week high as a signal of the end of a strong run, with the stock possibly peaking out before an impending period of decline.

For Puma Biotechnology Inc, the new 52-week high came on volume of 1.52 million. The stock has a float of 36.97 million shares and average daily volume of $1.37 million. It has a 50-day SMA of $40.01 and a 200-day SMA of $43.35.

For a complete fundamental analysis analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is also a component of the Russell 2000 Index, which is an invaluable tool for any small-cap investor. Consisting of the smaller 2,000 publicly traded companies of the 3,000 largest companies in America by market cap (which combine to make the broader Russell 3000 index), the Russell 2000 gives the most comprehensive snapshot of the small-cap market of any index out there.

What's more, the Russell 2000 is maintained by Russell Investments, a company committed to using rules-based methodologies to construct unbiased indices that differ from the committee-selected Dow Jones Industrial Average or S&P 500.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

More:
Puma Biotechnology Inc (PBYI) Breaks into New 52-Week High on May 30 Session - Equities.com

JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem


The Cerbat Gem
JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB)
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo JPMorgan Chase & Co. raised its position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 45.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional ...
iShares NASDAQ Biotechnology Index (IBB) Receiving Somewhat Favorable Media Coverage, Analysis ShowsSports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Folger Nolan Fleming Douglas Capital Management Inc.Chaffey Breeze
The Ameriprise Financial Inc. Increases Stake in iShares NASDAQ Biotechnology Index (IBB)BangaloreWeekly

all 10 news articles »

Read more from the original source:
JPMorgan Chase & Co. Acquires 245458 Shares of iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Bitop ‘made in Germany’ actives secures US distribution with Mibelle Biochemistry – CosmeticsDesign-Europe.com

Mibelle Biochemistry and Bitop, two cosmetics active ingredients manufacturers, have signed an exclusive distribution agreement for the US market.

The move will see Germany-based Bitop expanding itis global market presence, with Mibelle Biochemistry set to to supply Bitops actives from its US-based customer service centre, in White Plains New York.

By the terms of the agreement, Mibelle will process orders, provide customer service and coordinate US communications with Bitops international headquarters in Witten, Germany.

We are very happy and pleased about this co-operation, said Bitops CEO, Daniel Berger. With Mibelle Biochemistry, we have found a distribution partner who reflects our aspirations in excellent customer service.

United in values

Berger explained in a statement on the deal that Bitop and Mibelle Biochemistry share key values that will encourage the success of the new partnership, and expressed the companys anticipation of a stronger international profile in light of the deal.

Bitop and Mibelle Biochemsitry are both manufacturers of high quality actives. We share the same quality standards."

The CEO also hinted at ambitions to expand further once the actives manufacture has established itself within the US market.

Partnering with a manufacturer like Mibelle Biochemisyry is a grea opportunity for us to expand our market presence and visibility in the USA. Their US sales team is excellent and very well known in the market. This allows us to ensure the best possible technical support on site for our customers and further expansion, he confirmed.

Read more here:
Bitop 'made in Germany' actives secures US distribution with Mibelle Biochemistry - CosmeticsDesign-Europe.com

‘Young Sheldon’, ‘Grey’s Anatomy’ Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings – Deadline

Canadian broadcast network CTV has picked up four new U.S. comedies and nine dramas from this years Los Angeles Screenings for the 2017-18 season.

They are comedies The Big Bang Theory spinoff Young Sheldon, Me, Myself & I from CBSandRoseanne revival and The Mayor from ABC. Dramas include Shondalands untitled Greys Anatomy spinoff, which will premiere midseason, and new legal drama For the People. Also on the list are new ABC dramas The Good Doctor, Ten Days in the Valley, The Crossing, Deception, The Gospel of Kevin and Marvels Inhumansalong with Foxs The Gifted.

CTV and CTV Twos 2017-18 primetime schedules will be unveiled at the CTV Upfront on June 7 in Toronto.

CTVs strategically curated mix of the years most-buzzed about sitcoms and compelling dramas sets the stage for viewers to root for both heroes, families and even misfits with heart, said Mike Cosentino, SVP Content and Programming atCTV parent company Bell Media. We cant wait to share our powerful new slate with advertisers and viewers next week.

More:
'Young Sheldon', 'Grey's Anatomy' Spinoff Among 13 U.S. Series Picked Up By CTV LA Screenings - Deadline

Anatomy and physiology of ageing 5: the nervous system – Nursing Times

Download a print-friendly PDF file of this article here

John Knight is senior lecturer in biomedical science; Yamni Nigam is associate professor in biomedical science, both at the College of Human Health and Science, Swansea University.

The nervous system controls the activities of all body organs and tissues, receiving input from sensory organs and responding via effector organs. With around 100billion interconnected neurons, the brain is an extremely complex, and still poorly understood, organ. However we do understand, to some degree, how age affects it, as well as the nervous system as a whole. This fifth article in our series on the anatomy and physiology of ageing describes the age-related changes occurring in the brain, spinal cord and peripheral nerves. These changes lead to a gradual decline in cognitive function and a range of other issues, such as reduced bladder control or postural hypotension, but in health the brain normally continues to function adequately throughout life.

Knight J, Nigam Y (2017) Anatomy and physiology of ageing 5: the nervous system. Nursing Times [online]; 113: 6, 55-58.

The nervous system, along with the endocrine system, controls and integrates the activities of all the bodys organs and tissues. It receives and processes sensory input from organs such as the eyes, ears and skin, and responds through a variety of effector organs.

The main organ of the nervous system is the brain, which, with around 100billion interconnected neurons, is extremely complex; despite decades of research, its function remains poorly understood. Ageing leads to a progressive loss of neurons and depletion of neurotransmitters (Mather, 2016), these changes are usually associated with a gradual decline in cognitive function and influenced by environmental, genetic and lifestyle factors (Nyberg et al, 2012).

The ageing brain gradually loses neurons and supporting neuroglial cells (Fig 1). Between the ages of 20 and 60, the brain loses around 0.1% of neurons per year, after which the process speeds up (Esiri, 2007). By the age of 90, brain mass will have decreased by around 11% compared with individuals in their 50s, which equates to a loss of about 150g of neural tissue (Wyss-Coray, 2016). The remaining tissues harbour an increased concentration of potentially harmful materials such as iron, aluminium and free radicals.

Aged neural tissues also show increasing pigmentation, largely due to the deposition of two pigments: one brown, lipofuscin (Ottis et al, 2012), and one black, neuromelanin (Clewett et al, 2016). Lipofuscin is linked to amyloid

protein deposition and the formation of neurofibrillary tangles. These abnormal areas of neural tissue are often present at low densities in aged brain tissue, even in the absence of disease (Wyss-Coray, 2016); however, where Alzheimers disease is present, these are at high densities.

The loss of neurons is most apparent in the cerebral cortex. The grooves (sulci) that mark the surface convolutions (gyri) of the cerebral cortex are visibly deeper in brains of older people (Fig 1). It was originally thought that the frontal lobes were particularly vulnerable to neural loss, but similar losses have been observed in other cortical regions such as the parietal lobes (Fjell et al, 2014).

Fig 1. Three age-related changes in the brain

Fig 1. Three age-related changes in the brain

Structural changes in the frontal and parietal lobes are related to poor memory. Many people in their 80s have modest levels of amyloid protein deposition and retain their memory, while individuals with higher levels typically have a poorer working (short-term) memory (Nyberg et al, 2012). However, the role of amyloid deposition in impairing memory has recently been questioned and other factors, such as accumulation of tau proteins, may play a more important role (Brier et al, 2016).

The hippocampus has a key role in memory and the acquisition of new skills. With age, it loses a significant amount of neural tissue (Burke and Barns, 2006), which may explain why activities such as learning a new language become more difficult with advancing age. Recent research indicated that navigating a computer-generated virtual environment improved spatial awareness and reduced the shrinkage of the hippocampus, both in younger and older people (Lvdn et al, 2012). Virtual reality computer programs could therefore potentially be used to reduce shrinkage in this vital brain area.

Around 35% of people over the age of 70years have gait problems; while there are many contributing factors, including age-related changes to muscles and joints, the nervous system is also implicated. The somatic motor cortex located in the frontal lobes of the brain controls the movement of muscles involved in walking. From middle age onwards the neurons in this region show signs of atrophy (Manini et al, 2013), which can contribute to gait problems, potentially reducing mobility in older people (Rosso et al, 2013).

Ageing is associated with a gradual increase in the size of the ventricles (fluid-filled chambers) in the brain (Fig 1). This is likely to result from a progressive loss of the cells that line the ventricles. Enlarged ventricles fill with more cerebrospinal fluid, and are readily observable using techniques such as magnetic resonance imaging. On average, the volume of the ventricular system increases by around 2.9% per year; this expansion appears to accelerate with age, with people over the age of 70 having a median rate of expansion of 4.25% per year (Raz and Rodrigue, 2006). Although ventricular expansion is seen in most older people, the cognitive impact of this remains unclear.

The medulla oblongata and other areas of the brainstem lose fewer neurons than other regions of the brain. The brainstem is probably the best preserved region of the brain, which probably reflects its essential role in supporting life: it controls breathing, peristalsis, heart rate and blood pressure. However, the autonomic function of the brain does decline with age and this can compromise the bodys ability to respond quickly to internal and external environmental changes (Hotta and Uchida, 2010). Both branches of the autonomic nervous system (ANS) the parasympathetic and sympathetic branches are compromised with age (Parashar et al, 2016).

These changes can negatively affect older people. For example, the blunting of baroreceptor responses increases the risk of postural hypotension, so standing up suddenly can lead to falls and injury. Another negative consequence is the gradual loss of bladder control. To control micturition, the body relies on the interplay of sensory stretch receptors and the ANS (which together monitor bladder filling) and the conscious areas of the cerebral cortex (which signals when the bladder is full). To initiate micturition, the body needs motor control of the urinary sphincter. All these elements function less well with age, and these age-related changes combine with those in other body systems such as prostate enlargement in men and weakened pelvic floor muscles in women to reduce bladder sensitivity and control (Hotta and Uchida, 2010), which can lead to continence problems.

Cerebral blood flow decreases by around 0.38% per year, equating to a 27% decline over 70years of life (Chen et al, 2011). This is a direct consequence of the age-related changes in the cardiovascular system, and may be exacerbated in patients with atherosclerotic occlusion of the carotid arteries.

The blood-brain barrier (BBB) is formed primarily of tight junctions between adjacent endothelial cells within the blood vessels in the brain. Additionally, specialised neuroglial cells called astrocytes wrap around the cerebral vessels, forming a further physical barrier between the blood and neural tissues. The BBB is essential to prevent most pathogens and many toxic materials crossing into the neural networks and pathways of the brain, but its integrity appears to diminish with ag
e. A recent study indicates that, during normal ageing, the BBB is first weakened in the hippocampus, thereby allowing harmful substances and pro-inflammatory mediators to cross into this vital region of learning and memory. This breaching of the BBB may contribute to hippocampal shrinkage, and therefore to cognitive decline (Montagne et al, 2015).

Ageing is associated with a declining production of many neurotransmitters, including noradrenaline, glutamate, dopamine and serotonin. The decline in dopamine appears to be particularly important: dopamine modulates motor function and the acquisition of new skills, while also acting as one of the brains reward chemicals (Mather, 2016). The number of dopamine-producing neurons decreases as part of the normal ageing process, and this can adversely affect the ability to learn from past experiences. Recent studies show that many older people who boosted their levels of dopamine by taking L-DOPA (a drug normally used to treat Parkinsons disease) were learning as quickly as young adults again (Chowdhury et al, 2013).

Few studies have examined age-related changes to the spinal cord. A recent animal-model study shows an increase of cholesterol content in the ageing spinal cord, and the authors suggest this may potentially impair cord function (Parkinson et al, 2016).

Age-related changes to neurons and neuroglial cells appear to have little effect on spinal cord function. However, age-related changes to the vertebrae and intervertebral discs may increase pressure on the spinal cord and its branching nerve roots. This can slow down the conduction of nerve impulses along motor neurons, contributing to reduced muscular strength (Manini et al, 2013). Reduced sensory and motor conduction will increase the risk of injury due to poor coordination, poor balance and poor fine motor control.

With age, some peripheral neurons show a dying back (shrinkage of axonal length), loss of mitochondria and a degeneration of their insulatory myelin sheaths. Some of this damage may be caused by a rise in the concentrations of pro-inflammatory mediators in the body. The ageing body becomes less effective in clearing toxic metabolites and, as peripheral nerves are not afforded the protection of the BBB, this may contribute to peripheral nerve damage (Manini et al, 2013).

The loss of myelin slows the conduction of peripheral nerve impulses by around 5-10% (Joynt, 2000). In health, this reduction in conductivity causes few problems, but in older people with diabetes it may contribute to, and exacerbate, diabetic neuropathy. Damaged peripheral nerves are not repaired as efficiently in older people as in their younger counterparts, and some of these nerves are never repaired. This can contribute to reduced sensation and motor control.

In the absence of disease, intellectual ability can be retained throughout life. However, the gradual loss of neurons, depletion of neurotransmitters and slowing of nerve conduction may act together to slow down the processing of information. As a result, older people may take longer to complete certain tasks, and commonly experience the functional brain changes described below.

The loss of short-term and episodic memory is probably the earliest indication of age-related changes in the brain. Unlike what happens in dementia, the loss of short-term memory in the absence of disease does not affect life skills (such asthe ability to cook), but manifests as inconveniences (such as forgetting an item from the shopping list). Episodic memory (that is, remembering autobiographical events and their timings and sequence) also gradually declines in many older people (Fjell et al, 2014).

Verbal communication skills generally remain strong throughout life (Park and Reuter-Lorenz, 2009), but people over the age of 70years may have increasing problems using or recalling words. The ability to quickly name a common object usually remains stable up to the age of 70, but then declines with advancing years (Harada et al, 2013).

The progressive loss of neurons, reduction in impulse velocity and minor changes in the spinal cord lead to a slowing down of reaction times (Spirduso, 1995). This can create problems, particularly when a fast reaction is essential (for example, to step out of the way of oncoming traffic).

In England, around 22% of men and 28% of women over the age of 65 are affected by depression; in care homes, the figures are even greater, with around 40% of residents affected (Age UK, 2017).

It is almost impossible to determine whether depression in older people occurs as a normal consequence of ageing or as a result of chemical imbalances seen in types of depression that also affect younger people. Concentrations of neurotransmitters involved in lifting mood (particularly serotonin) diminish with age and this can contribute to symptoms of depression (Fidalgo et al, 2013). The Royal College of Psychiatrists estimates that >85% of depressed older people receive no help from the NHS (Age UK, 2017). Depression can often produce symptoms that mimic dementia (pseudo-dementia) and this often causes great anxiety.

On the whole, older people are less prone to emotional outbursts than younger people. This may be related to the relative structural stability of some of the brain regions linked to emotions. Most studies of the amygdalae which are heavily involved in impulsive behaviours and emotional reactions reveal little evidence of atrophy or shrinkage at a much slower rate than in other brain regions. Additionally, the amygdalae also appear to retain most of their functional activity in older age (Mather, 2016).

Because the overall neural mass reduces with age, neuroactive drugs such as antidepressants and neuroleptics can be more potent in older people. Doses normally prescribed to adults may induce confusion or delirium, and may therefore need to be adjusted.

How normal age-related changes to the brain can be distinguished from pathological changes associated with dementia (for example, Alzheimers disease) is hotly debated. The problem is that three of the main clinical features of Alzheimers disease loss of episodic memory, loss of brain tissue and amyloid deposition are also seen in apparently healthy older people with little or no evidence of dementia. However, it is generally recognised that the main risk factor for developing dementia is advancing age (Fjell et al, 2014).

Unlike cells in many other parts of the human body, most neurons do not undergo cell division so, when they dieas a result of age or injury, they are generally not replaced. Fortunately, the brain contains over 100billion interconnected neurons (the connectome) and many researchers agree that it has an in-built redundancy, known as the brain reserve. This is defined as the physical resources of the brain in terms of brain mass and number of neurons; a larger brain reserve is often associated with better outcomes after brain injury and in various neurological diseases (Tucker and Stern, 2011).

The brain reserve is not necessarily a good predictor of cognitive function (many people with normal cognition have significant brain atrophy), so the concept of cognitive reserve has emerged. People with a high cognitive reserve are able to use their brain reserve more efficiently to perform tasks, and this seems to happen through increased efficiency of functional connections between neurons (Marques et al, 2016).

Good predictors of a high cognitive reserve include high education level, high IQ, highly complex occupation and large amount of social interaction. Recent research indicates that cognitive ability may also be maintained by neural compensation, a process in which new circuits of neurons are recruited to perform tasks that were once carried out by aged ordamaged neural pathways (Steffener and Stern, 2012). In normal ageing, the brain reserve does decline but cognition ismaintained thanks to the brains in-built redundancy.

Keeping mentally active throughout life can reduce the effects of age on th
e nervous system (Mahncke et al, 2006), and engaging in social, sporting and mentally challenging activities can slow downthe decline in cognitive performance (Nyberg et al, 2012). It appears the more intellectually demanding and complex an individuals occupation, the better their cognitive performance in later years; however, in retirement, when the mental challenges of work are removed, this effect appears to decline.

Older people should be encouraged to engage in stimulating activities such as socialising, reading and games, which are thought to improve cognitive function and memory, as well as reduce the riskof depression. It is a common misconception that ageing naturally leads to conditions such as confusion, dementia and delirium. The human brains in-built redundancy allows it to adequately cope with the physical changes associated with ageing. Indeed, in the absence of disease, adequate mental function can be retained throughout life.

Age UK (2017)Later Life in the United Kingdom, January 2017.London: Age UK.

Brier MR et al (2016) Tau and A imaging, CSF measures, and cognition in Alzheimers disease.Science Translational Medicine;8: 338, 338ra66.

Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain.Nature Reviews Neuroscience;7: 1, 30-40.

Chen JJ et al (2011) Age-associated reductions in cerebral blood flow are independent from regional atrophy.Neuroimage;55: 2, 468-478.

Chowdhury R et al (2013) Dopamine restores reward prediction errors in old age.Nature Neuroscience;16: 5, 648-653.

Clewett DV et al (2016) Neuromelanin marks the spot: identifying a locus coeruleus biomarker of cognitive reserve in healthy aging. Neurobiology of Aging; 37: 117-126.

Esiri MM (2007) Ageing and the brain. Journal of Pathology; 211: 2, 181-187.

Fidalgo S et al (2013) Serotonin: from top to bottom. Biogerontology; 14: 1, 21-45.

Fjell AM et al (2014) What is normal in normal aging? Effects of aging, amyloid and Alzheimers disease on the cerebral cortex and the hippocampus. Progress in Neurobiology; 117: 20-40.

Harada CN et al (2013) Normal cognitive aging; Clinics in Geriatric Medicine; 29: 4, 737-752.

Hotta H, Uchida S (2010) Aging of the autonomic nervous system and possible improvements in autonomic activity using somatic afferent stimulation. Geriatrics and Gerontology International; 10: Suppl 1, S127-S136.

Joynt RJ (2000) Aging and the nervous system. In: The Merck Manual of Geriatrics. West Point PA: Merck & Co.

Lvdn M et al (2012) Spatial navigation training protects the hippocampus against age-related changes during early and late adulthood. Neurobiology of Aging; 33: 3, 620.e9-620.e22.

Mahncke HW et al (2006) Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proceedings of the National Academy of Sciences of the United States of America; 103: 33, 12523-12528.

Manini TM et al (2013) Aging and muscle: a neurons perspective. Current Opinion in Clinical Nutrition and Metabolic Care; 16: 1, 21-26.

Marques P et al (2016) The functional connectome of cognitive reserve. Human Brain Mapping; 37: 9, 3310-3322.

Mather M (2016) The affective neuroscience of aging. Annual Review of Psychology; 67: 213-238.

Montagne A et al (2015) Blood-brain barrier breakdown in the aging human hippocampus. Neuron; 85: 2, 296-302.

Nyberg L et al (2012) Memory aging and brain maintenance. Trends in Cognitive Sciences; 16: 5, 292-305.

Ottis P et al (2012) Human and rat brainlipofuscin proteome. Proteomics; 12: 15-16, 2445-2454.

Parashar R et al (2016) Age related changes in autonomic functions. Journal of Clinical and Diagnostic Research; 10: 3, CC11-CC15.

Park DC, Reuter-Lorenz P (2009) The adaptive brain: aging and neurocognitive scaffolding. Annual Review of Psychology; 60: 173-196.

Parkinson GM et al (2016) Perturbed cholesterol homeostasis in aging spinal cord. Neurobiology of Aging; 45: 123-135.

Raz N, Rodrigue KM (2006) Differential aging of the brain: patterns, cognitive correlates and modifiers. Neuroscience and Biobehavioral Reviews; 30: 6, 730-748.

Rosso AL et al (2013) Aging, the central nervous system, and mobility. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences; 68: 11, 1379-1386.

Spirduso WW (1995) Physical Dimensions of Aging. Champaign, Il: Human Kinetics.

Steffener J, Stern Y (2012) Exploring the neural basis of cognitive reserve in aging. Biochimica et Biophysica Acta; 1822: 3, 467-473.

Tucker AM, Stern Y (2011) Cognitive reserve in aging. Current Alzheimer Research; 8: 4, 354-360.

Wyss-Coray T (2016) Ageing, neurodegeneration and brain rejuvenation. Nature; 539: 7628, 180-186.

More:
Anatomy and physiology of ageing 5: the nervous system - Nursing Times

How Biotech Will Make Us Live Longer – Let’s Talk Anti-Aging – Labiotech.eu (blog)

Last week, at our first Labiotech Hangout,Philip had a chat with James Peyer, a partner at Apollo Ventures, to ask a few questions about how biotech istackling the anti-aging space.

For a long time, the anti-aging field has not seen much innovation,both due to a lack of scientific know-how as well as a lack of confidence on the part of pharma and regulatory agencies. Yet, in the past years, the field has started to turn into one of the most hyped areas in biotech, marked by the launch of companieslike Unity Biotechnology, which recently raked in $116Mfrom big names like Jeff BezosorCalico, which was co-founded by Google in 2013.

James Peyer from Apollo Ventures, a VC that focuses on biotechs in the age-related disease space, talked to Philip abouthow biotech is trying to solve the challenges of anti-aging, where the field is moving and how the first anti-aging therapies could enter the clinic within the next two years.

Referring to a review article on the hallmarks of aging, Peyer explains thatWithin the last 5 years, our understanding has gone from theory and hypothesis-driven to really coalescinga strong data-driven knowledge base.While there is no drug out there yet that is approved as an anti-aging treatment, James comments that The geroscience space has at least 80 mutations or chemicals that have been shown with some level of conviction to extend the healthylife span of a mouse.

However, the challenge will be to bring these compounds into the clinic. Anti-aging therapies are preventative medicines, meaning that the treatment is given before the actual occurrence of age-related disease so how do you run a clinical trial for such medicines?

Peyer mentions a group of scientists from Albert Einstein College of Medicinein New York that have been piloting such a preventative medicine study with a 7-year trial, totest whether the generic drug metformin can delay the onset of age-related conditions.This model of a 7-year clinical trial though, thats not really something that can be easily translated to a commercial model with a patented drug,he explains.

But whats gonna come out of those trials in the next 5-10 years are biomarkers that will give us a hint on whether or not adrug is working to reduce the risk of age-related diseases, and then that biomarker could be used in future trials,Peyer argues.

Apollo is following a slightly different path, though, as Peyer explains.The VC aims to go after geriatric syndromes, such as osteoarthritis, that are actually treatable medical conditions. Youll be really focussed on one indication thats a real clinical opportunity and move that towards the clinic just as you would with a traditional oncology drug or osteoarthritis drug.

Thats the opportunity that Apollo is really excited about and then, of course, there is the vision in the longer term that those two paths () will come together and create a world where we can actually do preventive clinical trials,Peyer adds.

Reflecting on who is buying in on that vision, Peyer says that the big players that are now coming into the area are technology players like Jeff Bezos or Google (). The internet space has attracted so much investment but the return profiles in this space actually look much worse compared to biopharma both in the US and the EU.

The biopharma space is actually just kicking ass right now! So when you see numbers like that and youre a tech investor it makes sense to make some moves.

Check out the video to hear more about which companies are leading the fieldandwhere Apollo is heading.

Shutterstock.com / BrunoWeltmann and Rustle

Merken

Read more here:
How Biotech Will Make Us Live Longer - Let's Talk Anti-Aging - Labiotech.eu (blog)

How To Navigate Your Child's Adolescence46:37 – WBUR

wbur

With guest hostJane Clayson. This program originally broadcast on September 19, 2016.

Anew parents guide to navigating adolescence. Its still a minefield out there.

Eye rolls. Blow-ups. Slammed doors. The silent treatment. Parenting adolescents can be challenging. Discouraging. Exhausting. Especially when you cant get them to answer a simple question like, How was your day? Or even look up from their cell phones. Whats a parent to do? What should a parent never do? Does it sometimes feel like payback for what you put your own parents through? This hourOn Point, expert advice for parents of teens. Jane Clayson

Sara Villanueva, professor of psychology in the School of Behavioral and Social Sciences at St. Edward's University in Austin. (@SaraVillanueva_)

Rob Evans, psychologist and executive director of the Human Relations Service Inc. in Wellesley, Massachusetts.

New York Times: When Teenagers Bristle At 'How Was School?' "In reality, few days are entirely fine, and none are entirely empty. So how do we improve on this perennial flop of an exchange?As adults we can often forget how stressful middle and high school can be. While some students are energized by school, most find their days taxing, even under the best conditions."

Proceedings of the National Academy of Sciences: Harnessing adolescent values to motivate healthier eating -- "Behavioral science has rarely offered effective strategies for changing adolescent health behavior. One limitation of previous approaches may be an overemphasis on long-term health outcomes as the focal source of motivation. The present research uses a rigorous randomized trial to evaluate an approach that aligns healthy behavior with values about which adolescents already care: feeling like a socially conscious, autonomous person worthy of approval from ones peers."

Your Teen: Top 10 Things To Expect In Middle School "Talk toparents whove been through middle school and youll often hear them lament that they had no idea what was coming. Parents are frequently eager for some middle school tips to help them survive, too."

This program aired on May 29, 2017.

Go here to read the rest:
How To Navigate Your Child's Adolescence46:37 - WBUR

Aesthetic Medicine: 5 top trends at the AMWC – Premium beauty

Skin-quality injections

All the big players have always had this kind of shallow micro-injection on the surface of the skin. Previously we called them Skin Boosters but they were underdeveloped and the focus was more on Hydration. It was positioned as an alternative to Mesotherapy (NCTF Filorga).

Today, studies show that skin quality isnt being addressed as much as it could be in doctors clinics. Many patients complain about Skin Fatigue the words being used by patients are: less radiant, dull, tired, dry and exhausted.

A newcomer was launched at the show by Allergan - Juvderm Volite - to treat skin quality; an HA (Hyaluronic-acid injection) to add smoothness, hydration and elasticity. Results last for 9 months.

Read more: http://www.allergan.com

Aesthetic medicine can be divided in 2 types of treatments:

The future is having both in one treatment: corrective & regenerative.

The use of autologous treatment such as PRP is being adopted in many clinics. Its largely used in medicine to treat sport injuries, arthritis and surgical wounds. Its an easy treatment to perform. The treatment uses the patients own blood. During a simple centrifuge process, the platelets and fibrins will be isolated from the blood. The resulting product (a liquid gel) is re-injected in the skin. The entire process takes 15-20 minutes. The difference between HA and this treatment for volume restoration is that the idea is not to fill the wrinkles but to stimulate the fibroblasts and the growth factors which will produce new collagen to regenerate the dermis, restore hydration and renew the skin.

There is a new treatment to treat the double-chin; even though doctors prefer to use the term submental fullness (double-chin makes patient feel like they are overweight).

Kybella (first launched in the US in 2016) is called Belkyra in Europe (it has just been launched in 2017). Kybella / Belkyra are a chin-fat reducing injections. The fat melting injection forsub-mental (under the chin) fat was approved by the FDA in April 2015. Its made from deoxycholic acid - a naturally occurring molecule, used by the body to rid unwanted fat. It breaks down the cell walls of fatty tissue. The body can then safely eliminate the unwanted tissue. As fat cells die off, they do not return. It has mainly been used to treat double chins but will be used for buttocks, neck and arms. It hurts, causes inflammation, but works. Results occur at 12 weeks. The treatment is popular amongst both men and women

Lifting threads as an alternative to facelifts are getting really popular in doctors offices. Redefining the face, restoring volume and reducing wrinkles are what the latest threads treatment can achieve. The lifting effect is immediate and discreet as it is the result of compressing the tissue and elevating the skin at the time of implanting the suture.

There is also a tissue stimulation effect with threads that comes from for example:

Universkin is a French cosmeceuticals brand with a mission to revolutionize the cosmeceuticals industry by challenging an obsolete cosmetics market and providing on-the-spot bespoke skincare.

Whats the concept?

The doctor will assess your skin care concerns based on a questionnaire which then colour codes the outcome to match specific ingredients. A tailor-made serum called Nexultra P will be created. All the three specific bespoke actives come in a powder form and are mixed in the serum base with a centrifuge-type machine.

The choice of three specific compounds following the patients exact skin needs:

The product includes only fresh actives and no preservatives, therefore it has a shelf-life of 6 weeks. It must be put into the fridge if the product hasnt been finished after 6 weeks. To learn more: http://www.universkin.com

See more here:
Aesthetic Medicine: 5 top trends at the AMWC - Premium beauty

Phlebotomy: Serena innovating on Dental Bioengineering to keep … – PRUnderground (press release)

At Serena Family & Cosmetic Dentistry in Clairemont, San Diego, we take pride in always being up to date on the latest technology and most innovative techniques in dentistry to benefit our patients and give them the quality service they deserve. Thats why we want to announce that Dr. Serena Kurt is now certified as a Phlebotomy Specialist. What is this and how does it benefit your Dental treatment? Let us explain.

Phlebotomy is the practice of drawing blood from patients and taking the blood specimens to the laboratory to prepare for testing. At first glance, this would seem unrelated to Dental Treatment or Dental Implants, but its not, it will benefit the patient in many ways that allow implants to settle much better once theyre installed, especially in drastic cases where the jawbone has deteriorated. However, this will allow you to heal faster and look as natural as ever.

Special state certification in the United States is required in California. To qualify to sit for an examination, candidates must complete a full phlebotomy course and provide documentation of clinical or laboratory experience. Dr. Kurt has now completed full certification to bring you all the commodities of this advanced treatment at an affordable price. Phlebotomy is used for Platelet Rich Plasma (PRP) procedure. PRP accelerates healing and enhances bone growth, which in turn stimulates osseointegration of dental implants. This means that if youre getting work done in our clinic, the procedure will allow the Doctor to add tissue to make regeneration and healing process much faster.

During the PRP procedure, a small amount of blood is drawn in preparation for dental implant treatment. PRP is a by-product of blood that is rich in platelets. Platelets are irregularly-shaped, colorless bodies that are present in the blood. Their sticky surface lets them, along with other substances, form clots to stop bleeding. Platelets contain growth factors (GFs), which serve as effective inducers of normal tissue repair. It also helps that this process is completely painless and will allow you to continue your daily activities. As we mentioned before, this process makes your teeth much more aesthetic, as it accelerates the natural process of rehabilitation, making it seem like you never had any work at all.

Due to the Platelets allowing your body to create new tissue by stimulating mesenchymal stem cells (MSCs). An article in The International Journal of Periodontics and Restorative Dentistry detailed a study regarding the use of Growth Factors in molar sites with bone defects. The authors of the article advocated the use of Growth Factors in immediate placement of implants at the time of tooth removal. They elaborate on how using this process practically guarantees the treatment will be successful, you will be able to preserve the bone, and soft tissue in the area wherein the implant is done, and superior esthetic results, helping you get back your beautiful smile in no time.

Like we stated before, few dental clinics in San Diego, especially in Clairemont, offer this treatment at the moment, but we keep innovating to meet the highest quality standards that you deserve, allowing us to compete with not only the top ranked Dental Clinics in the US, but the world. This is because not only can you get the highest quality materials and attention while getting, lets say, your crowns with us; but you can get them done with the most advanced German engineered machinery in as little as five minutes. Combined with this new technique, you wont have to worry about getting the quality treatment you need. Serena San Diego Dentist is the best option today for all the dental needs of you and your family.

With more than 20 years of expertise in the business, Dr. Serena Kurt and her San Diego dental office is your best option for the highest quality and personalized service you deserve.

About Serena San Diego Dentist

Serena Family & Cosmetic Dentistry offers top quality of dentistry in Clairemont, San Diego at affordable pricing! Dr. Serena Kurt has created more than 20,000 crowns and veneers during her 20 years of professional experience. As your official Clairemont, San Diego dentist and dental implant provider, Dr. Serena Kurt will ensure that you get only the finest and most suitable dental care that you cannot simply find anywhere else!

See the rest here:
Phlebotomy: Serena innovating on Dental Bioengineering to keep ... - PRUnderground (press release)

Biochemistry

Overview:

This is an introductory course in biochemistry, designed for both biology and chemical engineering majors.

A consistent theme in this course is the development of a quantitative understanding of the interactions of biological molecules from a structural, thermodynamic, and molecular dynamic point of view. A molecular simulation environment provides the opportunity for you to explore the effect of molecular interactions on the biochemical properties of systems.

This course assumes that students have taken introductory chemistry, including basic thermodynamics, as well as introductory organic chemistry. An introductory biology course is not a prerequisite for the course, but students would benefit from some prior exposure to biology, even at the high school level. Required mathematical skills include simple algebra and differential calculus.

The two main learning goals of the course are:

The course begins with amino acids and transitions into protein structure and thermodynamics. Protein-ligand binding is treated for both non-cooperative and cooperative binding using immunoglobulins and oxygen transport as examples. The enzymatic function of proteins is explored using serine and HIV proteases as examples. Enzyme kinetics is treated using steady-state kinetic analysis. Enzyme inhibition is treated quantitatively, using HIV protease as a key example.

Carbohydrate and lipids are presented in sufficient depth to allow the student to fully understand major aspects of central metabolism. The discussion of metabolism is focused on energy generation, fermentation, and metabolic control.

The course concludes with an extensive section on nucleic acid biochemistry. The focus of this section is to provide the student with sufficient background so that they are literate in the recombinant DNA technologies as they relate to protein production using recombinant methods.

After a treatment of molecular forces and solution properties, the course builds on molecular and energetic descriptions of fundamental monomeric building blocks to develop a comprehensive understanding of the biological function of polymers and molecular assemblies at the molecular and cellular level. In addition to multiple case studies, the course concludes with a capstone exercise that leads students through the steps required to produce recombinant proteins for drug discovery. The major topics in the course are:

Read this article:
Biochemistry

Global Market Study on Biochemistry Analyzers: Clinical Diagnostics Application Segment Projected to Retain Its … – PR Newswire (press release)

LONDON, May 29, 2017 /PRNewswire/ -- About the Report

Persistence Market Research in its latest report titled 'Biochemistry Analyzers Market: Global Industry Analysis and Forecast, 2016-2024' has presented a comprehensive research on the competition landscape in the global biochemistry analyzers market. The competition landscape portion of the global biochemistry analyzers market report begins by introducing the readers of the report to the company share analysis of all the important players operating in the global biochemistry analyzers market. This section of the report gives the breakup of the market share of all the key players operating in the global biochemistry analyzers market and observes that the market is highly fragmented owing to the presence of various companies, especially domestic players, in the global biochemistry analyzers market. In the subsequent section of the report, a competition dashboard is presented, which supplies information on various key players operating in the global biochemistry analyzers market; such as product offerings, regional presence and most important of all, strategies adopted by the key market players in order to succeed in the global biochemistry analyzers market. This kind of information is important for any new entrants or established players operating in the global biochemistry analyzers market as it provides insights on the kind of strategies being adopted by the leading market players so that they can emulate their success and also gauge the effectiveness of such strategies in different regions of the global biochemistry analyzers market.

Download the full report: https://www.reportbuyer.com/product/4921067/

In the subsequent sections of the competition landscape, individual information is supplied on the various key players operating in the global biochemistry analyzers market. The kind of information that is given includes company details, company description, product offerings, key financial information and key developments pertaining to the company. In addition, a strategic overview of the companies is also given that provides valuable information regarding the direction that the company is taking with respect to the market in the coming few years and how this will impact the global biochemistry analyzers market. Last but not the least, a SWOT analysis of all the key market players is also given in the competition landscape that provides deep insights regarding the key market players operating in the global biochemistry analyzers market and how the key market players are going to shape up the global market in the future with regards to their strengths and weaknesses and how they utilize the opportunities provided to them and tackle the various market threats and challenges.

Besides this, in the beginning of the report, a market forecast is given that comprises three scenarios, namely the conservative scenario, the likely scenario and the optimistic scenario. All of these three scenarios will result in different market numbers and growth rates and the report gives information why a particular scenario has been chosen as the most likely scenario in the global biochemistry analyzers market and also gives information regarding the other scenarios that may change the market forecasts, if at all, and the magnitude of the change on the forecasted market numbers and growth rates. Besides this, a section on regional biochemistry analyzers market volume (Unit Mn) analysis and forecast by product type, 2016-2024 is also given that provides an overview of the volume share in the regional biochemistry analyzers market and which region is the largest, most lucrative and fastest growing in terms of volume so that correct decisions pertaining to the global biochemistry analyzers market are taken. In addition, there is a section of the report devoted to the fully and semi-automated biochemistry analyzers price forecast by region, 2015 & 2024. This section of the report gives a price overview of the market region wise, so that important decisions on market growth and expansion can be taken by the players who wish to operate in the biochemistry analyzers market.

Another important and attractive feature of the global biochemistry analyzers report present by Persistence Market Research is the inclusion of PEST analysis. The detailed PEST analysis provided in the report gives all the important political, economic, social and technological aspects governing the global biochemistry analyzers market so that readers are fully aware of all the important factors that directly or indirectly affect the growth of the biochemistry analyzers market globally. Besides, information about the Laboratory Accreditation: Internal Quality Control (IQC), Laboratory Accreditation: External Quality Assessment Scheme (EQAS) are also given, adding more value to the report. Important guidelines by the Clinical and Laboratory Standards Institute (CLSI) are provided to enable readers to get an idea about the nuances of the global biochemistry analyzers market.

Also, in addition to all the above, the biochemistry analyzers market report contains an executive summary and also market definitions and the market taxonomy. Macroeconomic factors affecting the global biochemistry analyzers market along with the demand side drivers and supply side drivers are also given in order to give a deep overview of the global biochemistry analyzers market. Besides, restraints impacting the market along with opportunities and trends shaping up the biochemistry analyzers market also given to further add value to the report. The global biochemistry analyzers market analysis and forecast by product type, by end user, by modality, and by region is also given. This section of the report contains valuable information like Basis Point Share (BPS) analysis, Y-o-Y growth projections and market attractiveness analysis to provide in-depth insights into the global biochemistry analyzers market.

Market Segmentation

By Product Type

Semi-automated Biochemistry Analyzer Fully Automated Biochemistry Analyzer

By Application

Clinical Diagnostics Bioreactor Byproduct Detection Drug Development Applications Others

By Modality

Bench-top Floor standing

By End User

Hospitals Diagnostic Centers Pharmaceutical Companies Biotechnology Companies Academic Research Institutes Contract Research Organizations Academic Research Institutes

By Region

North America Latin America Europe Asia Pacific Download the full report: https://www.reportbuyer.com/product/4921067/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-market-study-on-biochemistry-analyzers-clinical-diagnostics-application-segment-projected-to-retain-its-dominance-through-2024-300465065.html

SOURCE ReportBuyer

http://www.reportbuyer.com

Read more:
Global Market Study on Biochemistry Analyzers: Clinical Diagnostics Application Segment Projected to Retain Its ... - PR Newswire (press release)

Monday on TV: ‘Grey’s Anatomy’ producer tries to improve on … – Salt Lake Tribune (blog)

It's lavish, multi-racial and a bit of a confusing mess.

And, apparently, being Shonda Rhimes will only get you so far. ABC ordered only seven episodes of "Still Star-Crossed," and it's airing them during the summer, with a debut on Memorial Day.

Elsewhere on TV

Stanley Cup Final (6 p.m., NBC/Ch. 5): Game 1 Nashville Predators at Pittsburgh Penguins

"Michael Jackson: Searching for Neverland" (6 p.m., Lifetime): Jackson life is recalled by his bodyguards. Really.

"Gotham" (7 p.m., Fox/Ch. 13): Gordon races to save the city from the Alice Tetch virus; some of Gotham's worst villains band together.

"The Bachelorette" (8 p.m., ABC/Ch. 4): Ashton Kutcher and Mila Kunis judge a contest; Kareem Abdul Jabbar plays basketball with the guys; one bachelor betrays Rachel.

"Lucifer" (8 p.m., Fox/Ch. 13): In the Season 2 finale, Charlotte accidentally burns a man to death and Lucifer has to keep Chloe from figuring out what happened.

"American Dad" (8 p.m. TBS): The town turns on Steve after he convinces the star quarterback of the arena-football team to quit playing.

"Angie Tribeca" (8:30 p.m., TBS): Holy 'Blindspot'! A naked woman emerges from a child's backpack and doesn't remember a thing.

National Memorial Day Concert (10 p.m, Ch. 11): Recorded on Sunday.

"Leah Remini: Scientology & the Aftermath" (10 p.m., A&E): In this two-hour special, Leah Remini and Mike Rinder explore the relationship between the Church of Scientology and its critics.

Read more here:
Monday on TV: 'Grey's Anatomy' producer tries to improve on ... - Salt Lake Tribune (blog)

Anatomy of a Goal: Morrow Makes it 2 – Massive Report

Welcome to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from Columbus Crew SCs previous match.

For match 14 of the 2017 MLS Season, we take a look at Toronto FC midfielder Justin Morrows 39th minute goal that put Toronto up 2-0 as part of the 5-0 win over Crew SC on Friday.

Heres a look at the finish from the Toronto FC midfielder.

It was hard to pick just one of Torontos five goals to break down, but Morrows goal is indicative of Torontos successful strategy in this match. When Columbus pushed up the field, Toronto looked to counter quickly, often playing a long pass into the Crew SC defense, looking to build off of a turnover or a win of possession by TFC.

During the first half, Crew SC lined up in what the official lineup called a 4-4-2, with Wil Trapp and Federico Higuain playing together in the midfield. This 4-4-2 sacrificed a defensive midfielder for an attacker, and left Trapp with much more ground to cover. As the lone defensive midfielder, Trapp was often the only player in the middle of the field, leaving acres of space for Toronto runners and creating chaos for the Crew SC defense.

Morrows goal begins with this Kekuta Manneh clearance. Manneh, lined up at forward, stuck to the left side of the field for much of the match. Here, Manneh has tracked back on defense, and seeing no other options, clears the ball up the field.

TFC center-back Eriq Zavaleta, pressured by Ola Kamara, heads the ball forward into the path of Michael Bradley.

Bradley immediately plays a risky pass back to Zavaleta, who is directed to clear the ball by fellow center-back Drew Moor. Notice here that Crew SC has 4 players in Toronto FCs defensive half. Wil Trapps midfield partner, Federico Higuain, provides the most pressure to Zavaletas clearance. By providing this pressure, Higuain leaves Trapp alone to cover much of the midfield.

Once Zavaleta clears the ball forward, Toronto immediately has a numerical advantage over Crew SC. Wil Trapp, highlighted near midfield, is almost totally alone in the midfield, because Higuain was pressuring the TFC center-backs. Jonathan Mensah is back the furthest on defense. Nicolai Naess is marking TFC striker Ben Spencer, while Harrison Afful doesnt seem to realize that Justin Morrow is totally unmarked right behind him.

As Waylon Francis receives the ball, he has two options: get the ball to Trapp, alone in the middle of the field, or send the ball up the sideline/out of bounds.

Francis opts to send the ball toward Trapp, but note the way the he heads the ball. Francis heads the ball with his momentum going away from the ball. Because his momentum is away from the ball, Francis slows the ball down, sending an incredibly weak and slow pass toward Trapp, who has to speed up to receive the ball.

Ben Spencer notices the weak pass, and immediately heads toward the ball.

Trapp and Spencer are in a footrace to the ball while the Crew SC defense drops into shape. Notice that Harrison Afful, just above the highlighted Ben Spender, is still unaware of Justin Morrow.

Trapp appears to be on track to win the ball, but has Ben Spencer bearing down on him. To make a successful pass, Trap would have to immediately play a first touch pass to one of the three Crew SC players near him: Nico Naess, Jonathan Mensah, or Waylon Francis.

However, as the above video shows, the ball takes a high bounce right before it gets to Trapp, and the Crew SC midfielder is unable to play a first touch pass. Forced to take an awkward touch on the ball, Trapp is dispossessed by the much larger Ben Spencer. Trapp is listed at 58 and Spencer is listed at 65 and Spencer easily knocks Trapp off the ball to spring the Toronto attack.

Having just dispossessed Trapp, Spencer has two options. Because Naess has shifted to cover him, Spencer will have to make a pass: a slotted ball to Tosaint Ricketts, who would be marked by Jonathan Mensah, or an easy pass to Justin Morrow, who is running at pace and will be just ahead of Harrison Afful. To Affuls credit, he finally noticed Morrow sprinting behind him, but will start his run too late to catch the TFC midfielder.

With Afful having pushed high up the field, notice now much space is open on the Crew SC defensive right flank.

Spencer opts to push the ball to the onrushing Morrow, who has already pushed ahead of Harrison Afful. As has happened a few times this year, Afful is forced to catch up with a midfielder who has built up pace while Afful was pushed up the field. This isnt necessarily Affuls fault, but the Crew SC right back, and the Crew SC managerial staff, have to realize that teams have punished Afful being pushed too far upfield multiple times this season. When Afful pushes that far up field, he does not have the luxury of being able to mentally switch off, and must be aware of his surroundings at all times. Afful was absolutely switched off until he noticed Morrow streaking over his left shoulder.

As Morrow approaches the ball, Afful catches up to him. If Afful can get in front of Morrow, he can force the TFC midfielder to take a difficult shot or make a cross to one of the, well-defended, TFC players in the box.

As Morrow prepares to shoot or pass, notice the Crew SC defense. For some reason, Naess has totally abandoned Ben Spencer, the tallest player on the field, who is now making an undefended run into the box. Naess may be attempting to get in front of Morrow, but the TFC midfielder already has a difficult angle on goal. Naess should have stayed with Spencer in an attempt to prevent TFCs tall striker from being open for a chipped cross.

But, Naesss leaving Spencer doesnt matter. Morrow fires a left-footed rocket at the near post. Afful has recovered, and does a good job to cut off Morrows crossing angles, forcing that shot from a tough angle. Afful should expect his goal keeper to have the near post covered from that angle.

However, Zack Steffen is caught flat-footed and is beaten to his near post by Morrows shot. Morrows shot here is excellent and perfectly placed, but Steffen cannot afford to be beaten to his near post from that angle.

Findings:

Read more from the original source:
Anatomy of a Goal: Morrow Makes it 2 - Massive Report

Helen Zille – Daily Maverick

In this post-truth era, it is becoming increasingly difficult to distinguish real scandals from bogus ones. Spotting the difference has become more important than ever, given the ease with which scandals are created, escalated and sent into orbit through social media.

In the parasitic relationship between social and conventional media, fake news is often used to generate outrage, and fake outrage, in turn, to generate news. Things that should generate outrage often pass unnoticed.

Outrage manufacturing becomes particularly marked in the months before political parties hold elective conferences for new leadership. During this period, internal jockeying for positions includes candidates raking as much muck on their opponents as possible.

Healthy scepticism is, therefore, a useful attitude with which to approach the many revelations that make their way into the media as South Africas major political parties approach their congress season.

It is fascinating to watch the links between some politicians and those journalists who are prepared to provide a public platform for their schemes. A few journalists even become pro-active agents in a partys internal battles and vendettas.

It was in this frame of mind that I read an article in last weeks Sunday Times headlined: Contractors paid for DA MECs bash.

The opening paragraph read, Acting DA provincial leader Bonginkosi Madikizela is facing allegations of impropriety after a swanky birthday bash in his honour was apparently partially funded by construction companies that benefit from projects financed by his department.

Despite the inclusion of a denial from Mr Madikizela himself, who is the provincial Minister of Human Settlements, the overwhelming impression left by the headline and the article is that contractors funded a party for the political head of a department that awards contracts and tenders worth billions annually. If that were true, it would (at the very least) be improper. At worst, it would indicate corruption.

So confident was the journalist of the latter that he publicly predicted the unfolding scandal would end Madikizelas career.

Before long, the lines were buzzing. Journalists wanted comment. The party hierarchy advised me to take urgent and immediate action.

The next day, the story escalated with a breathless front-page headline in the Cape Times screaming: Madikizela birthday party sleaze, followed by an article dripping in insinuations.

Experience, lifes best teacher, cautioned me to proceed carefully, gather as many facts as possible, and speak to the individuals involved before determining a course of action or making a public statement.

I knew at least two things:

So if it turned out that there were contractors who thought they could buy favours by sponsoring the event, they would end up sorely disappointed.

Nevertheless, if there had been such an attempt, it would have been wrong and action would be required. It was obviously important to establish the facts.

My first discussion was with Bonginkosi himself. I told him I was going to investigate the issue in as much detail as possible, so that I could determine an appropriate course of action. He welcomed my approach. He told me the party had been organised as a surprise for him. He thought he was going out to a birthday dinner with a group of friends, only to walk into a room full of guests shouting surprise.

What he knew about the background was as follows: He has, for years, been part of a 20-strong network of friends who support each other, specifically in times of celebration and bereavement, helping to raise money for events ranging from parties to funerals. This group (loosely based on the traditional stokvel saving model) meets on a regular basis. When Bonginkosi was elected the DAs interim Western Cape leader, they wanted to throw a celebration party for him.

Bonginkosi vetoed the idea. He said it was not appropriate in the circumstances, and could potentially be interpreted as lauding it over other candidates. They accepted his reservations, and later hatched a plan to give him a surprise birthday party instead. It was a closely guarded secret. After the event, when he enquired who had paid for it, they told him that a fundraising subcommittee had called on people to make donations. He accepted their word and thought nothing further of it. This was normal in his friendship circle, he said.

He confirmed the newspapers claim that Ms Pumla Zantsi, a partner in a construction firm doing business with the province, had contributed a multilayered, multicoloured cake, worth R3,000. That was the only contractor involved as far as he was aware.

Bonginkosi told me that he and Pumla were part of the mutually supporting friendship circle. They had been friends for 20 years, from the time they were both activists in Khayelitsha and long before he had even thought of joining the DA. For her part, Pumla had been a contractor to the province long before Bonginkosi became provincial Minister of Human Settlements. She had never used her presence in their stokvel network to seek a business advantage or political favour.

In any event, said Bongikosi, do you think that I can be bought for a birthday cake?

I thought about our conversation. A long-standing friend buys you (an admittedly expensive) cake, from her own pocket, and it turns into a scandal because her company does work for the province, and has done for years prior to your arrival on the scene? This put a completely different spin on a story that had been touted as a career-ending scandal.

But of course, there could conceivably be more to the story than that, so I investigated further. A party at the One & Only hotel does not come cheap. I started by making contact with Pumla Zantsi. She immediately agreed to meet and was entirely forthcoming. She explained that the group of friends had met over many weeks to organise the party. They had nominated a fund-raising committee who had approached prospective donors. She gave me the full donor list, ranging from people who had contributed to the incidentals (such as tea and coffee at their planning meetings) to those who had paid for the big ticket items such as the hotels bar tab. I then submitted the donors names (and the companies with which they are associated) to the Chief Financial Officer of the Department of Human Settlements, to determine if any of them are contractors to the Department or the Province. None, he responded.

I managed to get the telephone number of the major donor, a Mr G, who is based in Durban, where Bonginkosis sisters live, and where he once lived himself. He still has a large friendship network there. Mr G confirmed that he had covered the lions share of the cost, and that he has no business interests in the Western Cape and none in construction, and that he had elicited further donations from his network in Durban. None did work for the Western Cape either, he assured me.

Next, I had to check whether the people who said they were donors were the ones that actually paid for the party, so I contacted the relevant hotel manager and asked to see copies of the invoices and receipts. He was unable to give them to me, due to client confidentiality, so I asked the party organisers to source the documents for me.

They promptly did, and my office undertook a reconciliation which showed the accuracy of the information we had been given.

Next I scoured some of the photographs from the party and, with the help of the Department of Human Settlements, identified two contractors who attended as guests: Mr M and Mr P. Neither had been on the donor list, but I called them nevertheless to find out whether they had been asked to contribute, and whether they had done so. I wasnt asked for a cent and I didnt pay a cent, replied Mr M. He had been invited to the party because he had known Bonginkosi through political circles from the time he was still a member of the ANC.

Mr P
told a similar story. He was a subcontractor to Mr M, who had phoned during the festivities to encourage him to pop into the party. Mr P did.

By then, I had followed all the leads open to me. And I am confident that, on the information available, there is no more to the story than that. Meanwhile, the impression has been indelibly created in the minds of the newspaper-reading public that the minister has been involved in shady dealings involving contractors to his department paying for a lavish birthday party. The ineluctable deduction is that he is corrupt.

The ANC has reported the allegations to the Public Protector who has powers to probe the matter even more deeply than I did. I will pass on everything I have to assist her. And if anything further emerges, I will study it very carefully.

The one question I have not answered to my satisfaction is where, from inside the DA, this allegation came from in the first place. The newspaper has kept its sources anonymous. I have said it before and I say so again: when it is established that informants have leaked fake news to the media, they (and their motives) should become the focus of the story, because they have not acted in the public interest, only in their own.

It is time that this becomes standard practice in the media. Too much damage is done by anonymous sources spreading fake news, aided and abetted by journalists who know, if they are honest, that their revelations have nothing to do with speaking truth to power. DM

Read more:
Helen Zille - Daily Maverick

Aesthetic Medicine: 5 top trends at the AMWC – Premium beauty

Skin-quality injections

All the big players have always had this kind of shallow micro-injection on the surface of the skin. Previously we called them Skin Boosters but they were underdeveloped and the focus was more on Hydration. It was positioned as an alternative to Mesotherapy (NCTF Filorga).

Today, studies show that skin quality isnt being addressed as much as it could be in doctors clinics. Many patients complain about Skin Fatigue the words being used by patients are: less radiant, dull, tired, dry and exhausted.

A newcomer was launched at the show by Allergan - Juvderm Volite - to treat skin quality; an HA (Hyaluronic-acid injection) to add smoothness, hydration and elasticity. Results last for 9 months.

Read more: http://www.allergan.com

Aesthetic medicine can be divided in 2 types of treatments:

The future is having both in one treatment: corrective & regenerative.

The use of autologous treatment such as PRP is being adopted in many clinics. Its largely used in medicine to treat sport injuries, arthritis and surgical wounds. Its an easy treatment to perform. The treatment uses the patients own blood. During a simple centrifuge process, the platelets and fibrins will be isolated from the blood. The resulting product (a liquid gel) is re-injected in the skin. The entire process takes 15-20 minutes. The difference between HA and this treatment for volume restoration is that the idea is not to fill the wrinkles but to stimulate the fibroblasts and the growth factors which will produce new collagen to regenerate the dermis, restore hydration and renew the skin.

There is a new treatment to treat the double-chin; even though doctors prefer to use the term submental fullness (double-chin makes patient feel like they are overweight).

Kybella (first launched in the US in 2016) is called Belkyra in Europe (it has just been launched in 2017). Kybella / Belkyra are a chin-fat reducing injections. The fat melting injection forsub-mental (under the chin) fat was approved by the FDA in April 2015. Its made from deoxycholic acid - a naturally occurring molecule, used by the body to rid unwanted fat. It breaks down the cell walls of fatty tissue. The body can then safely eliminate the unwanted tissue. As fat cells die off, they do not return. It has mainly been used to treat double chins but will be used for buttocks, neck and arms. It hurts, causes inflammation, but works. Results occur at 12 weeks. The treatment is popular amongst both men and women

Lifting threads as an alternative to facelifts are getting really popular in doctors offices. Redefining the face, restoring volume and reducing wrinkles are what the latest threads treatment can achieve. The lifting effect is immediate and discreet as it is the result of compressing the tissue and elevating the skin at the time of implanting the suture.

There is also a tissue stimulation effect with threads that comes from for example:

Universkin is a French cosmeceuticals brand with a mission to revolutionize the cosmeceuticals industry by challenging an obsolete cosmetics market and providing on-the-spot bespoke skincare.

Whats the concept?

The doctor will assess your skin care concerns based on a questionnaire which then colour codes the outcome to match specific ingredients. A tailor-made serum called Nexultra P will be created. All the three specific bespoke actives come in a powder form and are mixed in the serum base with a centrifuge-type machine.

The choice of three specific compounds following the patients exact skin needs:

The product includes only fresh actives and no preservatives, therefore it has a shelf-life of 6 weeks. It must be put into the fridge if the product hasnt been finished after 6 weeks. To learn more: http://www.universkin.com

Read more:
Aesthetic Medicine: 5 top trends at the AMWC - Premium beauty